Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumithra J Mandrekar

Showing results (81-90 of 157) with videos related to

Pageof 16
Sort By:
Cancer|November 20, 2009
Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myelomaEric W Schaefer, Shaji Kumar, Angela Dispenzieri, et al.
Mayo Clinic Proceedings|July 17, 2010
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experiencePrashant Kapoor, Patricia T Greipp, Eric W Schaefer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2011
Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trialsMing-Wen An, Sumithra J Mandrekar, Megan E Branda, et al.
Cancer|March 22, 2012
Impact of disease progression date determination on progression-free survival estimates in advanced lung cancerYingwei Qi, Katie L Allen Ziegler, Shauna L Hillman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigationShauna L Hillman, Sumithra J Mandrekar, Brian Bot, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2007
A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycinAlfred F Furth, Sumithra J Mandrekar, Angelina D Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancerGrzegorz S Nowakowski, Andrea K McCollum, Matthew M Ames, et al.
Journal of Clinical Pharmacology|February 26, 2013
Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjectsAlexander K Berg, Sumithra J Mandrekar, Katie L Allen Ziegler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 24, 2010
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory studyAraba A Adjei, Oreste E Salavaggione, Sumithra J Mandrekar, et al.
Annals of Surgical Oncology|July 8, 2021
Impact of the COVID-19 Pandemic on Cancer Clinical TrialsJudy C Boughey, Rebecca A Snyder, Olga Kantor, et al.
Pageof 16

Showing results (81-90 of 157) with videos related to

Sort By:
Pageof 16
Cancer|November 20, 2009
Residual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myelomaEric W Schaefer, Shaji Kumar, Angela Dispenzieri, et al.
Mayo Clinic Proceedings|July 17, 2010
Idiopathic systemic capillary leak syndrome (Clarkson's disease): the Mayo clinic experiencePrashant Kapoor, Patricia T Greipp, Eric W Schaefer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2011
Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trialsMing-Wen An, Sumithra J Mandrekar, Megan E Branda, et al.
Cancer|March 22, 2012
Impact of disease progression date determination on progression-free survival estimates in advanced lung cancerYingwei Qi, Katie L Allen Ziegler, Shauna L Hillman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 19, 2010
Evaluation of the value of attribution in the interpretation of adverse event data: a North Central Cancer Treatment Group and American College of Surgeons Oncology Group investigationShauna L Hillman, Sumithra J Mandrekar, Brian Bot, et al.
Cancer Chemotherapy and Pharmacology|October 3, 2007
A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycinAlfred F Furth, Sumithra J Mandrekar, Angelina D Tan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2006
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancerGrzegorz S Nowakowski, Andrea K McCollum, Matthew M Ames, et al.
Journal of Clinical Pharmacology|February 26, 2013
Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjectsAlexander K Berg, Sumithra J Mandrekar, Katie L Allen Ziegler, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 24, 2010
Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory studyAraba A Adjei, Oreste E Salavaggione, Sumithra J Mandrekar, et al.
Annals of Surgical Oncology|July 8, 2021
Impact of the COVID-19 Pandemic on Cancer Clinical TrialsJudy C Boughey, Rebecca A Snyder, Olga Kantor, et al.
Pageof 16